Stable solid forms of enclomiphene and enclomiphene citrate

Abstract

The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

1 . Enclomiphene acetate of formula (IV): 
       
         
           
           
               
               
           
         
       
     
     
         2 . Enclomiphene acetate according to  claim 1  which is characterized by the following  1 H-NMR (400 MHz, DMSO-d 6 ) peaks: δ=7.45-7.37 (m, 2H), 7.36-7.29 (m, 5H), 7.28-7.21 (m, 3H), 6.86 (dt, J=9.1; 3 Hz, 2H), 6.71 (dt, J=9.1; 3 Hz, 2H), 3.95 (t, J=5.8 Hz, 2H), 2.79 (t, J=5.8 Hz, 2H), 2.59 (q, J=7.5 Hz, 4H), 1.92 (s, 3H), 0.97 (t, J=7.5 Hz, 6H). 
     
     
         3 . Enclomiphene acetate according to  claim 1  which characterized by the following  13 C-NMR (100 MHz, DMSO-d 6 ) peaks: 172.6, 157.9, 142.2, 140.4, 139.3, 133.1, 131.7, 130.1, 129.7, 128.7, 128.69, 128.61, 127.9, 114.5, 66.1, 51.4, 47.3, 21.6, 11.8. 
     
     
         4 . Pharmaceutical compositions comprising Enclomiphene acetate of formula (IV) according to  claim 1  and one or more pharmaceutical acceptable excipients. 
     
     
         5 . A method for the treatment ovulatory dysfunction or polycystic ovary syndrome, comprising administering the Enclomiphene acetate of  claim 1  to a patient in need thereof.